Celea Therapeutics

Advancing transformative treatments for serious respiratory diseases

Boston, United States · Founded 2025 · $255.0M raised

Employees
11–50
Founded
2025
Business Model
B2B
Total Funding
$255.0M
Last Round
$180.0M Series BJul 2026
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Celea Therapeutics is a clinical-stage biopharmaceutical company dedicated to advancing transformative treatments for serious respiratory diseases, founded by PureTech Health in 2025. Its lead program, deupirfenidone (LYT-100), is a next-generation antifibrotic entering Phase 3 development for idiopathic pulmonary fibrosis (IPF), designed as a strategically modified version of an approved IPF therapy with the potential to become the new standard of care. The company's landmark SURPASS-IPF trial is the first industry-sponsored head-to-head Phase 3 trial in IPF.

Summary

Celea Therapeutics is a Biotech company based in Boston, United States, founded in 2025. It has raised $255.0M in total across 2 rounds, most recently a $180.0M Series B round in Jul 2026. Investors include PureTech Health, RA Capital Management and Leaps by Bayer.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BJul 2026
$180.0M

Sign up to see all 2 events

Funding: Seed through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Celea Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/celea-therapeutics"><img src="https://indexed.vc/api/badge/company/celea-therapeutics" alt="Celea Therapeutics on Indexed.vc" width="260" height="76" /></a>